Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study

By afschroeder • August 20, 2025

Kim YJ, Merle P, Finn RS, Kudo M, Klümpen HJ, Lim HY, Ikeda M, Granito A, Masi G, Gerolami R, Cho SB, Hsu CH, Huang YH, Jeng LB, Kim DY, Lin SM, Pinter M, Shao G, Kato N, Kurosaki M, Numata K, Kuo KK, Mao Y, Lin YJ, Zhu K, Twumasi-Ankrah P, Khan J, Awan M, Ozgurdal K, Qin S. Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study. Liver Cancer. 2024 Dec 18;14(4):391-407. doi: 10.1159/000542285. PMID: 40831889; PMCID: PMC12360744.

Tags: Hematology/Oncology, Hepatocellular carcinoma, observational study, prospective, Publications, real-world evidence, regorafenib

Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T,[...]

Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab

Cheon J, Ryoo BY, Chon HJ, Kim HD, Ryu MH, Kim KP, Kang B, Finn RS, Chan SL, Yoo C. Multicenter Phase 2 Trial of[...]

Dysregulated SASS6 expression promotes increased ciliogenesis and cell invasion phenotypes

Hargreaves E, Collinson R, Jenks AD, Staszewski A, Tsalikis A, Bodoque R, Arias-Garcia M, Abdi Y, Al-Malki A, Yuan Y, Natrajan R, Haider S, Iskratsch[...]